Inhibitory effects on pulmonary metastases of low-dose consecutive administration of cisplatin on sarcoma-bearing mice

Anticancer Res. 2003 Jan-Feb;23(1A):309-13.

Abstract

Low-dose consecutive CDDP administrations have been reported to be effective in cancer treatment. We studied the inhibitory effects on pulmonary metastasis of bolus versus low-dose consecutive administration of CDDP chemotherapy for sarcoma-bearing mice, and evaluated the differences in responses to two types of therapy. Significant reductions (p < 0.01) in the number of pulmonary metastases were observed in the low-dose consecutive administration group compared to the control group, and in the bolus group compared to the control group. No significant difference in the number of metastases between the low-dose consecutive administration group and the bolus group was observed (p = 0.43). This study suggests that low-dose consecutive CDDP administration would be as effective as bolus CDDP administration, which is currently popular. Also, low-dose consecutive CDDP administrations may contribute to the attenuation of the adverse drug reactions expected by patients with bone and soft tissue tumors who are undergoing chemotherapy.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Body Weight / drug effects
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / pathology
  • Bone Neoplasms / secondary
  • Cisplatin / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Fibrosarcoma / drug therapy*
  • Fibrosarcoma / pathology
  • Fibrosarcoma / secondary
  • Humans
  • Lung Neoplasms / prevention & control*
  • Lung Neoplasms / secondary*
  • Male
  • Mice
  • Mice, SCID
  • Soft Tissue Neoplasms / drug therapy*
  • Soft Tissue Neoplasms / pathology
  • Soft Tissue Neoplasms / secondary
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Cisplatin